OCC 2014:家庭血压远程监测—社区高血压管理新模式

2014-06-05 广东省人民医院 冯颖青 OCC2014每日新闻

家庭自测血压的重要地位诊室血压仍是高血压诊断的标准方法,但家庭自测血压更能反应患者实际血压,更能预测靶器官损害,因此2010年欧洲高血压学会颁布了家庭自测指南,我国也在2011 年起草了血压测量指南。欧美国家高血压患者家庭自测比率>50% 甚至达到75%。而2007 年北京功能社区职业人群调查显示仅10.1% 开展家庭自测血压。21 世纪血压监测信息化平台(云技术)的建设及逐步推广使得“遥测

家庭自测血压的重要地位

诊室血压仍是高血压诊断的标准方法,但家庭自测血压更能反应患者实际血压,更能预测靶器官损害,因此2010年欧洲高血压学会颁布了家庭自测指南,我国也在2011 年起草了血压测量指南。欧美国家高血压患者家庭自测比率>50% 甚至达到75%。而2007 年北京功能社区职业人群调查显示仅10.1% 开展家庭自测血压。21 世纪血压监测信息化平台(云技术)的建设及逐步推广使得“遥测血压”成为国外崭新的血压管理模式。

家庭血压远程监测系统

家庭血压远程监测系统是运用蓝牙、无线远程网(GPRS/CDMA/3G)、Internet 广域网等前沿通信技术建立连接大型医院- 区县医院-基层社区卫生服务中心的三级远程血压诊断随访网络。远程血压管理系统架构包括血压计、手机、物联网、互联网及医护监控电脑。技术原理是通过内置有记忆功能的自动电子血压计自动测量血压,通过手机等现代智能通信设备,将采集到的血压信息经处理后上传到网络中心(云平台),处理后发送至监控终端,直接进入电子档案,医护人员可实时动态全程管理。因此远程血压管理系统是基于物联网、云计算通信技术的智慧医疗产品,是家庭自测血压技术与现代高科技技术融合的结晶。

国外早在21 世纪初已开展远程血压监测,2000 年日本Sukoyaka family21 项目、2003 年美国IDEATEL 计划、2004 年欧盟五国( 英国、德国、荷兰、瑞典、西班牙)行动式健康照护(mobihealth)计划以及2010 年加拿大高血压教育计划(CHEP)均利用这种现代科技技术为患者提供了很好的自我管理平台,并实现更周全的照护服务,节省医疗资源,也为医生提供了全面随访和预后评估平台。通过上述远程血压监测,能否改善高血压患者的血压控制率呢? Parati G教授在TeleBP care 研究中发现,自测血压远程传输组较常规血压监测组血压控制率显著提高,同时医疗费用减少。2013 ESH/ESC 高血压指南提出信息与通信技术是未来血压管理的发展趋势。

远程血压管理的意义

患者方面 远程短时间内获得专家指导建议,利于把握最佳诊治时机;减少就诊费用;充分调动患者参与治疗的积极性,提高治疗率和控制率,改善依从性。

医生方面 对于初次诊断高血压的患者可以进行家庭自测血压并实时监控,利于排除白大衣高血压和明确诊断隐匿性高血压;远程管理患者,及时调整药物,提高工作效率,节约社区医生工作成本;有利于科研数据管理,避免人工输入错误及血压0 尾数偏好,规范、准确、真实获得患者血压数值。

社会方面 缓解百姓医疗需求与医疗资源结构反差之间的矛盾;远程慢病管理推动医疗资源共享和重大疾病防治,有利于卫生行政部门指南和政策的制订,最终提高中国高血压知晓率、治疗率和控制率。

远程血压监测技术是实现远程慢病管理的关键,能够提供更准确的诊断依据、更贴身的病情护理、更广阔的健康普及,突破目前医疗数据样本的地域性限制,为高血压领域大样本、多中心、跨地域的患者研究提供了依据。

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (5)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=884025, encodeId=7f21884025ec, content=好, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=76d12257050, createdName=12177770m58暂无昵称, createdTime=Wed Sep 09 23:08:52 CST 2020, time=2020-09-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1946129, encodeId=5f971946129ce, content=<a href='/topic/show?id=f6fb102e02e4' target=_blank style='color:#2F92EE;'>#高血压管理#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=102702, encryptionId=f6fb102e02e4, topicName=高血压管理)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1ac22500003, createdName=1249842em09(暂无昵称), createdTime=Wed Jul 23 00:35:00 CST 2014, time=2014-07-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1344293, encodeId=98c41344293d0, content=<a href='/topic/show?id=683a88964b0' target=_blank style='color:#2F92EE;'>#血压管理#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=88964, encryptionId=683a88964b0, topicName=血压管理)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=793a2500200, createdName=12498e5fm12(暂无昵称), createdTime=Sat Jun 07 02:35:00 CST 2014, time=2014-06-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1352990, encodeId=68b81352990b3, content=<a href='/topic/show?id=1d931321816' target=_blank style='color:#2F92EE;'>#OCC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13218, encryptionId=1d931321816, topicName=OCC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Sat Jun 07 02:35:00 CST 2014, time=2014-06-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1395604, encodeId=501913956048b, content=<a href='/topic/show?id=7a89e4036eb' target=_blank style='color:#2F92EE;'>#社区#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=74036, encryptionId=7a89e4036eb, topicName=社区)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=96f62500201, createdName=12498e67m28暂无昵称, createdTime=Sat Jun 07 02:35:00 CST 2014, time=2014-06-07, status=1, ipAttribution=)]
    2020-09-09 12177770m58暂无昵称

    0

  2. [GetPortalCommentsPageByObjectIdResponse(id=884025, encodeId=7f21884025ec, content=好, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=76d12257050, createdName=12177770m58暂无昵称, createdTime=Wed Sep 09 23:08:52 CST 2020, time=2020-09-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1946129, encodeId=5f971946129ce, content=<a href='/topic/show?id=f6fb102e02e4' target=_blank style='color:#2F92EE;'>#高血压管理#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=102702, encryptionId=f6fb102e02e4, topicName=高血压管理)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1ac22500003, createdName=1249842em09(暂无昵称), createdTime=Wed Jul 23 00:35:00 CST 2014, time=2014-07-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1344293, encodeId=98c41344293d0, content=<a href='/topic/show?id=683a88964b0' target=_blank style='color:#2F92EE;'>#血压管理#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=88964, encryptionId=683a88964b0, topicName=血压管理)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=793a2500200, createdName=12498e5fm12(暂无昵称), createdTime=Sat Jun 07 02:35:00 CST 2014, time=2014-06-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1352990, encodeId=68b81352990b3, content=<a href='/topic/show?id=1d931321816' target=_blank style='color:#2F92EE;'>#OCC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13218, encryptionId=1d931321816, topicName=OCC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Sat Jun 07 02:35:00 CST 2014, time=2014-06-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1395604, encodeId=501913956048b, content=<a href='/topic/show?id=7a89e4036eb' target=_blank style='color:#2F92EE;'>#社区#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=74036, encryptionId=7a89e4036eb, topicName=社区)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=96f62500201, createdName=12498e67m28暂无昵称, createdTime=Sat Jun 07 02:35:00 CST 2014, time=2014-06-07, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=884025, encodeId=7f21884025ec, content=好, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=76d12257050, createdName=12177770m58暂无昵称, createdTime=Wed Sep 09 23:08:52 CST 2020, time=2020-09-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1946129, encodeId=5f971946129ce, content=<a href='/topic/show?id=f6fb102e02e4' target=_blank style='color:#2F92EE;'>#高血压管理#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=102702, encryptionId=f6fb102e02e4, topicName=高血压管理)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1ac22500003, createdName=1249842em09(暂无昵称), createdTime=Wed Jul 23 00:35:00 CST 2014, time=2014-07-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1344293, encodeId=98c41344293d0, content=<a href='/topic/show?id=683a88964b0' target=_blank style='color:#2F92EE;'>#血压管理#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=88964, encryptionId=683a88964b0, topicName=血压管理)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=793a2500200, createdName=12498e5fm12(暂无昵称), createdTime=Sat Jun 07 02:35:00 CST 2014, time=2014-06-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1352990, encodeId=68b81352990b3, content=<a href='/topic/show?id=1d931321816' target=_blank style='color:#2F92EE;'>#OCC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13218, encryptionId=1d931321816, topicName=OCC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Sat Jun 07 02:35:00 CST 2014, time=2014-06-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1395604, encodeId=501913956048b, content=<a href='/topic/show?id=7a89e4036eb' target=_blank style='color:#2F92EE;'>#社区#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=74036, encryptionId=7a89e4036eb, topicName=社区)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=96f62500201, createdName=12498e67m28暂无昵称, createdTime=Sat Jun 07 02:35:00 CST 2014, time=2014-06-07, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=884025, encodeId=7f21884025ec, content=好, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=76d12257050, createdName=12177770m58暂无昵称, createdTime=Wed Sep 09 23:08:52 CST 2020, time=2020-09-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1946129, encodeId=5f971946129ce, content=<a href='/topic/show?id=f6fb102e02e4' target=_blank style='color:#2F92EE;'>#高血压管理#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=102702, encryptionId=f6fb102e02e4, topicName=高血压管理)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1ac22500003, createdName=1249842em09(暂无昵称), createdTime=Wed Jul 23 00:35:00 CST 2014, time=2014-07-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1344293, encodeId=98c41344293d0, content=<a href='/topic/show?id=683a88964b0' target=_blank style='color:#2F92EE;'>#血压管理#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=88964, encryptionId=683a88964b0, topicName=血压管理)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=793a2500200, createdName=12498e5fm12(暂无昵称), createdTime=Sat Jun 07 02:35:00 CST 2014, time=2014-06-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1352990, encodeId=68b81352990b3, content=<a href='/topic/show?id=1d931321816' target=_blank style='color:#2F92EE;'>#OCC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13218, encryptionId=1d931321816, topicName=OCC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Sat Jun 07 02:35:00 CST 2014, time=2014-06-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1395604, encodeId=501913956048b, content=<a href='/topic/show?id=7a89e4036eb' target=_blank style='color:#2F92EE;'>#社区#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=74036, encryptionId=7a89e4036eb, topicName=社区)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=96f62500201, createdName=12498e67m28暂无昵称, createdTime=Sat Jun 07 02:35:00 CST 2014, time=2014-06-07, status=1, ipAttribution=)]
    2014-06-07 zhaojie88
  5. [GetPortalCommentsPageByObjectIdResponse(id=884025, encodeId=7f21884025ec, content=好, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=76d12257050, createdName=12177770m58暂无昵称, createdTime=Wed Sep 09 23:08:52 CST 2020, time=2020-09-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1946129, encodeId=5f971946129ce, content=<a href='/topic/show?id=f6fb102e02e4' target=_blank style='color:#2F92EE;'>#高血压管理#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=102702, encryptionId=f6fb102e02e4, topicName=高血压管理)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1ac22500003, createdName=1249842em09(暂无昵称), createdTime=Wed Jul 23 00:35:00 CST 2014, time=2014-07-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1344293, encodeId=98c41344293d0, content=<a href='/topic/show?id=683a88964b0' target=_blank style='color:#2F92EE;'>#血压管理#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=88964, encryptionId=683a88964b0, topicName=血压管理)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=793a2500200, createdName=12498e5fm12(暂无昵称), createdTime=Sat Jun 07 02:35:00 CST 2014, time=2014-06-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1352990, encodeId=68b81352990b3, content=<a href='/topic/show?id=1d931321816' target=_blank style='color:#2F92EE;'>#OCC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13218, encryptionId=1d931321816, topicName=OCC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Sat Jun 07 02:35:00 CST 2014, time=2014-06-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1395604, encodeId=501913956048b, content=<a href='/topic/show?id=7a89e4036eb' target=_blank style='color:#2F92EE;'>#社区#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=74036, encryptionId=7a89e4036eb, topicName=社区)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=96f62500201, createdName=12498e67m28暂无昵称, createdTime=Sat Jun 07 02:35:00 CST 2014, time=2014-06-07, status=1, ipAttribution=)]

相关资讯

ACC 2014:(IMPACT研究)远程监测指导抗凝治疗并不优于诊室评估

2014年美国心脏病学会年会(ACC 2014)公布的IMPACT研究表明,在置入起搏器/心脏再同步治疗除颤器(ICD/CRT-D)的慢性心力衰竭(CHF)患者中,房性快速型心律失常(AT)远程监测并不优于诊室评估AT和基于医生判断,指导抗凝治疗也如此。研究者指出这是一个有意思的观点,可能在特定患者人群中(如不能经常去门诊的老年人群)具有实用性。 此项研究按照1:1比例将置入ICD或CRT-D的